urinary tract infections

Novel biomarker accurately identifies infants with UTIsUrinary neutrophil gelatinase-associated lipocalin (uNGAL) is highly sensitive and specific for diagnosing urinary tract infections (UTIs), according to a study in febrile children aged up to 24 months.
Meropenem/Vaborbactam for Complicated UTIs
Meropenem/Vaborbactam for Complicated UTIsVabomere combines a carbapenem and a beta-lactamase inhibitor as a treatment for complicated urinary tract infections.
Treating UTIs in the age of antibiotic resistance: Strategies for the practicing OB/GYNOb/gyns have witnessed how development of antibiotic resistance has affected disease management in our specialty. Increased resistance of Neisseria. Gonorrhea (N. gonorrhea) to penicillins and quinolones, emergence of methicillin-resistant staphylococcus aureus (MRSA) and resistance of Group B Streptococcus to erythromycin and clindamycin have led us to modify our antibiotic treatment regimens.
What’s behind the drop in hospital-acquired conditions?
What’s behind the drop in hospital-acquired conditions?A report from the Department of Health and Human Services indicates positive momentum in efforts to combat hospital-acquired conditions, but experts say more can be done.
Serious risks associated with SGLT2 inhibitorsFDA is warning about ketoacidosis and urinary tract infections associated with the relatively new class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Invokana and Jardiance.
FDA approves new antibacterial drug AvycazFDA has approved ceftazidime-avibactam (Avycaz, Actavis and Forest), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.
FDA drug approvals December 2014
Drug combo reduces UTIs in kids by up to 80%Long-term use of a combination antimicrobial trimethoprim–sulfamethoxazole (TMP/SMZ) reduces the risk of recurrent urinary tract infection (UTI) by up to 80% in children with the urinary condition vesicoureteral reflux compared to placebo, according to a study published online May 4 in the New England Journal of Medicine.
Poor prescribing practices for antibiotics put patients at riskPoor antibiotic prescribing practices are putting patients at risk for allergic reactions, super-resistant infections, and deadly diarrhea cause by Clostridium difficile, according to new report from the Centers for Disease Control and Prevention (CDC).